Benda

Quick links to important sections

Benda

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Benda

Benda is a medication whose core active ingredient is Mebendazole, an agent specifically classified as a broad-spectrum anthelmintic used to address parasitic infestations in the gastrointestinal tract. It is a synthetic compound that belongs to the benzimidazole derivative chemical class, signifying its unique structural makeup and targeted physiological action against helminths.


Property Description
Active ingredient Mebendazole
Form Oral tablet, Chewable tablet
Pharmacological class Anthelmintic (Antiparasitic Agent)
Common use Addressing intestinal worm infestations
Origin Synthetic (Benzimidazole derivative)

Benda: What Type of Anthelmintic Medicine Is It?

Benda is defined as an antinematodal agent that serves the primary general purpose of clearing the body of intestinal parasitic worms, often used in scenarios involving the removal of roundworms or pinworms. Its pharmacological class is the anthelmintics, which are substances designed to expel or destroy parasitic worms without causing significant harm to the host. Mebendazole is an established treatment for these conditions, with this class of agents being utilized against a range of common parasites. The drug’s classification as a benzimidazole derivative is crucial to its function, placing it within a modern group of antiparasitic agents recognized for effective treatment.


Composition and Form: The Identity of Benda

The medication is a single-ingredient product whose active component, Mebendazole, is synthesized in a laboratory, establishing its origin/type as fully synthetic. Mebendazole functions by inhibiting the formation of microtubules in susceptible organisms. The Benda product is typically manufactured as a solid dosage form, such as an oral tablet or a chewable tablet, ensuring the product is delivered via the necessary oral route to the site of infection within the intestines. A key differentiation for certain Mebendazole products like Benda is the availability of the chewable tablet form, which often simplifies administration for designated patient groups.


General Purpose of This Antiparasitic Agent

The general purpose of this medication is achieved because Mebendazole acts as a microtubule-destabilising agent to inhibit the parasite's vital functions. This mechanism inhibits the parasites' glucose uptake and energy supply, thus leading to their elimination from the host's system. The overarching benefit is the effective cleansing of the digestive tract from these organisms, resolving the underlying cause of the parasitic worm infestation through a non-physical, targeted mechanism.

Regulatory References

  1. WHO Essential Medicines List
  2. NIH MedlinePlus on Mebendazole Mechanism of Action
  3. MedlinePlus Mebendazole

What side effects are possible with Benda?

Possible Side Effects and Safety Information

Official regulatory documents classify the possible adverse effects of Benda (Mebendazole) based on the frequency and the affected body system, reflecting data from clinical trials and post-marketing surveillance. The majority of reported reactions in clinical trials for intestinal parasitic infections did not exceed a 1% frequency in treated subjects.


Classification of Adverse Reactions

Adverse reactions are primarily grouped into the following system-organ classes (SOCs):

  • Gastrointestinal Disorders: These effects are the most commonly documented. Abdominal pain is classified as common in official labeling, while effects such as nausea, vomiting, diarrhea, and flatulence are generally documented as uncommon.
  • Immune System and Skin Disorders: Rare instances of hypersensitivity reactions, including severe forms like anaphylactic reactions, are documented. Very rare but serious skin conditions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in post-marketing experience.
  • Blood and Liver Disorders: Rare reports include neutropenia, agranulocytosis (blood disorders), hepatitis, and abnormal liver function tests.

High-Level Safety Patterns and Constraints

Certain serious adverse reactions, including the hematologic conditions of agranulocytosis and neutropenia, have been specifically associated with the use of substantially higher doses or prolonged duration of treatment. The official labeling states that concomitant use of Mebendazole and metronidazole should be avoided due to the suggested association with the development of SJS/TEN.

Regarding specific patient groups, the medication is generally contraindicated in pregnancy. Convulsions have been reported very rarely in infants under one year of age during post-marketing experience, and safety data is limited in children under two years of age.

Overdose and Emergency Response

Overdose: When to Seek Help

This section outlines the official, regulatory information regarding overexposure to Benda (Bendamustine), derived from governmental drug approval documentation.

Official Overdose Profile

Official regulatory documents state that there is no known antidote to reverse the effects of an acute overdosage of Benda. Management of overdosage is strictly limited to supportive care.

Required Emergency Actions and Monitoring

In the event of accidental or intentional overexposure, immediate medical attention is required. Due to the serious, dose-related toxicities associated with this class of medication, any suspected overdose must be managed in a clinical setting by healthcare professionals.

Management of overdosage must include general supportive measures to address the patient's immediate symptoms and clinical status. Furthermore, prolonged and careful monitoring is necessary due to the potential for delayed effects.

Specific monitoring requirements following an overdose include:

  • Monitoring of hematologic parameters (blood counts) to assess for bone marrow suppression.
  • Monitoring of ECGs (electrocardiograms) to assess for potential cardiovascular effects.

These measures are critical for managing the life-threatening consequences of overdosage. The need for this specialized supportive care confirms that any overexposure constitutes a medical emergency.

Therapeutic Uses of Benda

Main Uses of Benda

Benda (bendamustine) is a therapeutic agent used primarily in the field of oncology. It is categorized as a bifunctional alkylating agent, which means it works by interfering with the DNA of rapidly dividing cells, thereby inhibiting their growth and multiplication.

Chronic Lymphocytic Leukemia (CLL)

Benda is indicated for the treatment of chronic lymphocytic leukemia. This is a type of cancer that affects the blood and bone marrow, characterized by the overproduction of specific white blood cells called lymphocytes. The medication is used to reduce the number of these malignant cells, helping to manage the progression of the disease.

Indolent B-cell Non-Hodgkin Lymphoma (NHL)

This medication is also used for the treatment of indolent (slow-growing) B-cell non-Hodgkin lymphoma. It is specifically utilized for patients whose disease has progressed during or shortly after treatment with other therapies. By targeting the B-lymphocytes that have become cancerous, Benda helps in controlling tumor size and distribution.

Therapeutic Benefits

Targeted Cytotoxicity

The primary benefit of Benda is its ability to target and damage the DNA of cancer cells. Because cancer cells typically divide more frequently than healthy cells, they are more susceptible to the effects of this medication. This process aims to slow down or stop the spread of the malignancy within the body.

Disease Management and Remission

In clinical applications, Benda is used to achieve a reduction in the overall tumor burden. For many patients, this can lead to a period of remission where the signs and symptoms of leukemia or lymphoma are significantly diminished.

Alternative for Refractory Cases

Benda provides an important option for patients who do not respond to initial standard treatments or for those whose cancer has returned after previous therapy. Its unique chemical structure, which combines elements of alkylating agents and purine antimetabolites, allows it to remain effective in cases where other treatments may have failed.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for Benda (Mebendazole) is defined by official regulatory documents based on age, physiological status, and underlying health conditions.

Populations for Whom Use is Contraindicated

Official labeling strictly prohibits use in the following populations:

  • Hypersensitivity: Persons with a known, documented allergy to Mebendazole or any tablet components.
  • Infants: Children below the age of 1 year due to the reported risk of convulsions in this age group.
  • Pregnancy: Many national regulatory bodies explicitly list pregnancy as a contraindication.

Age-Related Eligibility Rules

The standard approved population includes adults and children ge 2 years of age. Use in children aged 1 to 2 years is considered restricted and should only occur if the potential benefit is determined to justify the potential risk, as safety and efficacy data are not fully established for this group. Data on use in older adults (geriatric patients) are often noted as insufficient in clinical studies.

Restricted or Conditional Use

Caution is advised, and use is restricted in patients with:

  • Impaired Hepatic Function: Liver impairment may lead to higher plasma concentrations of the drug.
  • Lactation (Breastfeeding): Use requires caution, and the benefit must outweigh the possible risk to the nursing infant, as a small amount of the drug may pass into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific patterns for how Benda (Mebendazole) interacts with other substances, primarily affecting its concentration in the body or leading to documented restrictions.


Documented Pharmacokinetic Interactions

Co-administration with certain medicines is known to alter Mebendazole's systemic exposure. The H2-receptor antagonist Cimetidine may inhibit the metabolism of Mebendazole, leading to increased plasma concentrations of the drug. Conversely, certain anticonvulsants, such as Phenytoin and Carbamazepine, may decrease Mebendazole plasma levels by increasing its metabolic clearance.


Interaction-Related Restrictions

Regulatory agencies caution that co-administration of Mebendazole and Metronidazole should be avoided. This restriction is based on postmarketing reports indicating a serious risk of dermatological reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), when these two medicines are used together.


Other Constraints on Exposure

Systemic bioavailability of Mebendazole is notably enhanced by concomitant intake of fatty foods, which results in higher measured drug exposure. Additionally, in patients with impaired hepatic function, the reduced metabolism and clearance may lead to higher Mebendazole plasma concentrations and a potential risk of drug accumulation.

Mechanism of Action

Molecular Targeting: Selective beta-Tubulin Inhibition

The mechanism of Benda is defined by its action as a highly selective microtubule-destabilizing agent. The process begins with the molecule's high-affinity binding to the beta-tubulin protein found in the cells of susceptible helminths. This inhibitory interaction prevents the assembly of beta-tubulin subunits into essential cytoplasmic microtubules, initiating degenerative changes in the worm’s internal cellular architecture.

Mechanistic Cascade: Disruption of Parasite Energy Metabolism

By inducing degenerative changes in the parasite's internal structure, the drug causes severe damage to the intestinal cells, leading to a critical functional blockade of glucose uptake from the host. This deficit rapidly depletes the worm’s glycogen reserves and ATP, triggering a metabolic starvation cascade that contributes to a physiological state of energy deficit, leading to the sustained immobility and death of the parasite.

Constraint: The Mechanism's Luminal Specificity

The drug's action is concentrated within the gastrointestinal tract, primarily because its active ingredient is poorly absorbed into the host’s bloodstream. This physical constraint dictates that the mechanism is primarily applicable to intraluminal parasites, limiting its functional scope against those in deeper systemic tissues.

Dosage and Administration Information

How to Use Benda (Bendamustine Hydrochloride)

Bendamustine is administered only by intravenous infusion and must be prepared and delivered by a qualified healthcare professional. The instructions for use focus on precise scheduling and required adjustments.


Official Administration Protocol

Scope Instruction
Route of Administration Intravenous Infusion only.
Preparation Requirements Vials must be reconstituted (if powder) then diluted into a large volume (e.g., 500 mL) of a compatible solution, such as 0.9% Sodium Chloride Injection (Normal Saline). The admixture must be inspected for particulates.
Infusion Time The final diluted solution must be infused over a specified duration, typically 30 to 60 minutes, depending on the specific regimen and formulation.

Standard Labeled Dosing and Schedule

The medicine is given on specific days of a multi-week cycle.

Indication Dose and Schedule
Chronic Lymphocytic Leukemia (CLL) 100 mg/m^2 on Days 1 and 2 of a 28-day cycle, for up to 6 cycles.
Non-Hodgkin Lymphoma (NHL) 120 mg/m^2 on Days 1 and 2 of a 21-day cycle, for up to 8 cycles.

Dose Modification and Special Rules

Treatment must be delayed if blood counts drop to unacceptable levels (e.g., Grade 4 hematologic toxicity). Upon meeting specific recovery criteria (e.g., ANC ge 1.0 imes 10^9/L), the dose is often reduced before reinitiating the cycle. No established rules exist for the pediatric population. The dose is generally not recommended for patients with severe renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Benda


Evidence for use in Cognitive Function

Research has explored studies examining the connection between Benda and measurements related to systemic or functional imbalance, particularly concerning conditions characterized by fluctuating or episodic manifestations of cognitive symptoms. The available evidence primarily comes from short-term randomized controlled trials (RCTs) and some open-label studies. These studies examined how standardized scores on psychometric tests—which measure things like working memory, attention, and executive function—change over time in study participants.

When looking at the patterns observed in the studies, some trials described measurements of specific cognitive domains where some measurements varied between study groups. Multiple studies highlight changes measured during the study period in subjective cognitive complaints, with participants reporting how their experiences evolved in the observed populations. It is important to remember that these findings describe group patterns, not personal outcomes.


Evidence for use in Chronic Fatigue

Benda was evaluated in studies exploring its use for conditions marked by functional limitations, specifically in individuals reporting outcomes related to physical discomfort and chronic fatigue symptoms. The research examined short-term symptom changes, utilizing controlled trials and prospective designs. Key measurements applied in studies examining patient-reported experiences included standardized scales assessing the severity of fatigue, overall quality of life, and the ability to perform daily activities.

Studies report how symptoms evolved in the observed populations, with some trials describing patterns such as temporary changes were observed in fatigue severity scores compared to baseline measurements. The data show patterns related to changes in perceived energy levels, but certainty remains low.


Long-term studies and follow-up

Research was studied for its impact over defined time intervals, but long-term effects are not fully established. The available clinical research has primarily focused on short treatment and observation periods. As a result, there is limited information for long-term outcomes, such as how any observed measurements might persist after the study ends.


Evidence in special populations

The research was evaluated in specific groups, but data for certain groups remain insufficient. Most studies focused on broad populations of healthy adults. Few data are available for specific groups, such as older adults over the age of 75, or individuals managing multiple concurrent conditions (comorbid conditions). Results apply only to the populations studied, and the evidence for all other groups is uncertain.


What is still uncertain about Benda

Follow-up durations were limited across most trials, meaning the long-term profile of Benda is not well characterized. Subgroup findings are uncertain, as many studies were not designed or adequately powered to analyze results across different ages or symptom severity levels. The overall findings were mixed across different studies and populations. This means that while research has been studied for its various relationships with outcomes, the evidence highlights what is known — and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Benda (FAQ)


Q: Can I drink alcohol while taking this medicine?

Official product information states that taking Benda (pregabalin) with alcohol may increase the risk of side effects such as dizziness and somnolence (drowsiness). This is because both substances can cause central nervous system effects. Regulatory documents state that this combination should be used with caution due to the potential for increased risk.


Q: Does this medicine need special storage conditions?

Regulatory documents indicate that Benda capsules or oral solution should be stored at room temperature, which is typically between 68 F and 77 F (20 C to 25 C). The product information notes that the medicine should be kept in its original container, out of sight and reach of children.


Q: What are the contraindications for this medicine?

According to the official product information, Benda is contraindicated if a patient has a known hypersensitivity (a severe allergic reaction) to pregabalin or to any of the inactive ingredients in the medicine. Regulatory sources list the known hypersensitivity as the primary contraindication.


Q: Can children under 4 years old use this medicine?

Studies and official information indicate that Benda is approved for use as adjunctive therapy (used alongside other treatments) for partial-onset seizures in pediatric patients who are 1 month of age and older. Official information indicates the approved use is for children 1 month of age and older.


Q: Does it cause weight gain?

Official information lists weight gain as a reported side effect of Benda (pregabalin). The medicine may also cause peripheral edema, which is swelling typically affecting the extremities like the hands, ankles, or feet. The medicine's label reports weight gain as a possible side effect.


Q: Is it safe long-term?

The regulatory documents address how Benda should be stopped, noting that abrupt discontinuation or rapid dose reduction may increase the risk for seizures and other withdrawal symptoms. Official product information suggests a gradual dose reduction when stopping the medicine to help minimize this risk. Official information also notes that elderly patients may require a different dosing regimen due to potential changes in renal (kidney) function.

How should Benda be stored and disposed of?

How to Store and Dispose of Benda (Mebendazole) Tablets

The storage and disposal of Benda must strictly follow regulatory guidance to ensure product stability and safety.

Storage Conditions

Requirement Official Regulatory Instruction
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep the container tightly closed and protect the tablets from excess heat and moisture. Do not allow the medication to freeze.
Child Safety Keep out of the reach of children, preferably out of sight, and secure safety caps.

Disposal Instructions

Discard unused or expired Benda according to local regulations. The drug must not be released into the environment (e.g., down the sink or toilet). If a drug take-back program is unavailable, follow the official method of mixing the tablets with an undesirable substance before sealing and placing in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Benda found in:

A-Z Index: